Literature DB >> 16738802

Apoptotic, necrotic, or fused tumor cells: an equivalent source of antigen for dendritic cell loading.

Nicolas Larmonier1, Delphine Mérino, Alexandra Nicolas, Dominique Cathelin, Angélique Besson, Andrew Bateman, Eric Solary, François Martin, Emmanuel Katsanis, Bernard Bonnotte.   

Abstract

The identification of the most efficient strategy for tumor antigen loading of dendritic cells (DCs) remains a challenge in cancer immunotherapy protocols. Autologous dead tumor cells have been demonstrated to constitute an acceptable source of multiple tumor-associated antigens (TAA) to pulse DCs. However the optimal approach for inducing cell death that would lead to effective endocytosis and activation of DCs remains controversial. In this study we have induced and defined 3 distinct mechanisms of tumor cell death (apoptosis, necrosis and fusion-mediated cell death), and investigated their differential effects on DCs. Bone marrow-derived DCs demonstrated comparable uptake of primary apoptotic, necrotic, or fused dead tumor cells. Furthermore, the distinct modes of cancer cell death had analogous potential in activating the transcription factors NF-kappaB and STAT1 and in maturing DCs, resulting in an equally effective stimulation of immune T cells. The current study therefore provides further informations on the use of dead whole tumor cells as antigen sources for effective active anti-cancer immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16738802     DOI: 10.1007/s10495-006-8765-0

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  14 in total

1.  Optimization of dendritic cell loading with tumor cell lysates for cancer immunotherapy.

Authors:  Paul Hatfield; Alison E Merrick; Emma West; Dearbhaile O'Donnell; Peter Selby; Richard Vile; Alan A Melcher
Journal:  J Immunother       Date:  2008-09       Impact factor: 4.456

2.  T-cell responses to survivin in cancer patients undergoing radiation therapy.

Authors:  Dörthe Schaue; Begonya Comin-Anduix; Antoni Ribas; Li Zhang; Lee Goodglick; James W Sayre; Annelies Debucquoy; Karin Haustermans; William H McBride
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

3.  Low-dose chemotherapeutic agents regulate small Rho GTPase activity in dendritic cells.

Authors:  Galina V Shurin; Irina L Tourkova; Michael R Shurin
Journal:  J Immunother       Date:  2008-06       Impact factor: 4.456

4.  Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.

Authors:  Narek Shaverdian; Aaron E Lisberg; Krikor Bornazyan; Darlene Veruttipong; Jonathan W Goldman; Silvia C Formenti; Edward B Garon; Percy Lee
Journal:  Lancet Oncol       Date:  2017-05-24       Impact factor: 41.316

5.  Signaling pathways induced by a tumor-derived vaccine in antigen presenting cells.

Authors:  Jessica Cantrell; Claire Larmonier; Nona Janikashvili; Sara Bustamante; Jennifer Fraszczak; Amanda Herrell; Tamara Lundeen; Collin J LaCasse; Elaine Situ; Nicolas Larmonier; Emmanuel Katsanis
Journal:  Immunobiology       Date:  2009-10-31       Impact factor: 3.144

6.  Allogeneic effector/memory Th-1 cells impair FoxP3+ regulatory T lymphocytes and synergize with chaperone-rich cell lysate vaccine to treat leukemia.

Authors:  Nona Janikashvili; Collin J LaCasse; Claire Larmonier; Malika Trad; Amanda Herrell; Sara Bustamante; Bernard Bonnotte; Michael Har-Noy; Nicolas Larmonier; Emmanuel Katsanis
Journal:  Blood       Date:  2010-12-01       Impact factor: 22.113

Review 7.  Personalized dendritic cell-based tumor immunotherapy.

Authors:  Nona Janikashvili; Nicolas Larmonier; Emmanuel Katsanis
Journal:  Immunotherapy       Date:  2010-01       Impact factor: 4.196

8.  PIAS1 and STAT-3 impair the tumoricidal potential of IFN-γ-stimulated mouse dendritic cells generated with IL-15.

Authors:  Neale T Hanke; Collin J LaCasse; Claire B Larmonier; Darya Alizadeh; Malika Trad; Nona Janikashvili; Bernard Bonnotte; Emmanuel Katsanis; Nicolas Larmonier
Journal:  Eur J Immunol       Date:  2014-05-23       Impact factor: 5.532

9.  Recognition of live phosphatidylserine-labeled tumor cells by dendritic cells: a novel approach to immunotherapy of skin cancer.

Authors:  Michael R Shurin; Alla I Potapovich; Yulia Y Tyurina; Irina L Tourkova; Galina V Shurin; Valerian E Kagan
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

10.  Efficacy of dendritic cells matured early with OK-432 (Picibanil), prostaglandin E2, and interferon-alpha as a vaccine for a hormone refractory prostate cancer cell line.

Authors:  Changhee Yoo; Hyun-Ah Do; In Gab Jeong; Hongzoo Park; Jung-Jin Hwang; Jun Hyuk Hong; Jin Seon Cho; Myong-Soo Choo; Hanjong Ahn; Choung-Soo Kim
Journal:  J Korean Med Sci       Date:  2010-08-14       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.